Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I/IIa open-label dose-escalation study of 2B3-101 in brain metastases or recurrent malignant glioma
NL-OMON39207Phase 1Recruiting
- Sponsor
- 2-BBB Therapeutics
- Start
- Aug 2011
- Modality
- Small Molecules, Liposomes → Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 1, open-label trial of doxorubicin glutathione pegylated liposomal in brain metastases, malignant glioma, breast cancer and 3 more (7 arms), sponsored by 2-BBB Therapeutics. Primary endpoints: Dose-limiting toxicities and maximum tolerated dose and Safety and tolerability. Started Aug 2011; status: recruiting.
02
Drugs
doxorubicin glutathione pegylated liposomal
03
Conditions
brain metastasesmalignant gliomabreast cancersmall cell lung cancer (SCLC)melanoma
Beyond the preview
Go deeper on NL-OMON39207.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON39207.